stoxline Quote Chart Rank Option Currency Glossary
  
Boston Scientific Corporation (BSX)
67.33  -0.09 (-0.13%)    04-19 16:00
Open: 67.87
High: 68.03
Volume: 6,951,266
  
Pre. Close: 67.42
Low: 66.905
Market Cap: 98,968(M)
Technical analysis
2024-04-19 5:08:15 PM
Short term     
Mid term     
Targets 6-month :  79.34 1-year :  80.83
Resists First :  67.93 Second :  69.2
Pivot price 68.07
Supports First :  65.87 Second :  54.8
MAs MA(5) :  67.65 MA(20) :  68.05
MA(100) :  62.79 MA(250) :  56.52
MACD MACD :  0.2 Signal :  0.4
%K %D K(14,3) :  25 D(3) :  31.8
RSI RSI(14): 47.4
52-week High :  69.2 Low :  48.34
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ BSX ] has closed above bottom band by 12.7%. Bollinger Bands are 42.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 68.15 - 68.71 68.71 - 69.08
Low: 65.75 - 66.36 66.36 - 66.78
Close: 66.52 - 67.48 67.48 - 68.12
Company Description

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Headline News

Sat, 20 Apr 2024
Boston Scientific Co. (NYSE:BSX) Shares Bought by SVB Wealth LLC - Defense World

Fri, 19 Apr 2024
Boston Scientific Corp. stock underperforms Friday when compared to competitors - MarketWatch

Thu, 18 Apr 2024
FDA Classifies Boston Scientific's Recall For Device To Stop Blood Flow As 'Most Serious' - Yahoo Finance

Wed, 17 Apr 2024
Boston Sci issues corrective recall for Obsidio Embolic over safety concerns - Seeking Alpha

Tue, 16 Apr 2024
What's in Store for Boston Scientific (BSX) in Q1 Earnings? - Yahoo Finance

Wed, 10 Apr 2024
Boston Scientific (BSX) Faces Rising Costs, Competition - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NYSE
Sector:
Healthcare
Industry:
Medical - Devices
Shares Out 1,470 (M)
Shares Float 1,460 (M)
Held by Insiders 0.1 (%)
Held by Institutions 93.6 (%)
Shares Short 12,430 (K)
Shares Short P.Month 9,440 (K)
Stock Financials
EPS 1.07
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 13.14
Profit Margin 11.1 %
Operating Margin 16.5 %
Return on Assets (ttm) 4.4 %
Return on Equity (ttm) 8.5 %
Qtrly Rev. Growth 14.8 %
Gross Profit (p.s.) 0
Sales Per Share 9.68
EBITDA (p.s.) 2.45
Qtrly Earnings Growth 285.6 %
Operating Cash Flow 2,500 (M)
Levered Free Cash Flow 1,880 (M)
Stock Valuations
PE Ratio 62.92
PEG Ratio 2.4
Price to Book value 5.12
Price to Sales 6.95
Price to Cash Flow 39.59
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android